

Table S1. Oligonucleotide primer sequences.

Target Gene	Primers (forward and reverse)	Product Size (bp)	GenBank Accession No.	Primer Efficiency (%)
GAPDH	CGGAGTCAACGGATTTGG CCTGGAAGATGGTGATGG	218	NM_002046	99.2
CD80	TGGCTGGTCTTTCTCACTTC TCAACAGAAACATTGTGACCAC	97	NM_005191	96.1
CD86	GGAACCAACACAATGGAGAG AAACACGCTGGGCTTCATC	94	NM_006889	98.2
CD163	GCAATGGGGTGGACTTACCT TCACCATGCTTCACTTCAACAC	126	NM_004244.5	99.1
CD206	TCGGGTTTATGGAGCAGGTG TGAACGGGAATGCACAGTT	121	NM_002438.3	96.6
IL6	TAGTGAGGAACAAGCCAGAG GCGCAGAATGAGATGAGTTG	184	NM_000600	96.1
TNFα	AGCCCATGTGTAGCAAACC GGACCTGGGAGTAGATGAGGTA	149	NM_000594	96,2
CCL3/MIP1α	ACCAGTTCTCTGCATCACTT CTTGGTTAGGAAGATGACACC	146	NM_002983.2	99.5
CXCL10/IP10	GGTGAGAAGAGATGTCTGAATCC GTCCATCCTTGGAAAGCACTGCA	102	NM_001565	95,6
IL10	CTTTAAGGGTTACCTGGGTTG CTTGATGTCTGGGTCTTGG	100	NM_000572	99.7
TGFβ1	CAACAATTCCTGGCGATACCT TAGTGAACCCGTTGATGTCC	196	NM_000660	98.3
CCL18	CTGCCTCGTCTATACCTCC CGGCCTCTCTTGGTTAGGA	111	NM_002988.3	91.4




Figure S1. Flow cytometry evaluation of macrophages markers CD68, CD86 and CD206 evaluated both on CD14 positive (CD14+) and negative (CD14-) synoviocytes ($n = 4$). Data are expressed as percentage of positive cells and represented as box plot with median and minimum and maximum.

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).